Ritlecitinib for patchy hair loss in teens and adults with alopecia areata

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 3 interventional trial evaluating ritlecitinib at 50 mg and 100 mg versus placebo for moderate alopecia areata. Participants will take the study drug or placebo daily at home for 24 weeks, with potential dose changes after 24 weeks. The trial aims to determine safety and the effect on scalp hair loss over six months, with eligibility based on SALT score and duration of the current episode. Lead sponsor is Pfizer, with sites in California, Florida, and Illinois.

Why it matters

Who can join: the full rules

Key Inclusion Criteria

* 18 years or older (or the minimum age of consent in accordance with local regulations) at screening. Adolescents (12 to \<18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB/EC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled
* Have a clinical diagnosis of AA with no other etiology of hair loss.
* Have \>20% to \<50% hair loss of the scalp, as measured by SALT.
* Current AA episode of hair loss ≥6 months and ≤10 years (Current episode is defined as the continuous period of AA-related scalp hair loss since the last time the subject had no visible scalp patches).

Key Exclusion Criteria

1\. Diseases or conditions affecting hair loss, including:

* Other types of alopecia (including, but not limited to, traction and scarring alopecia, telogen effluvium). Participants with androgenetic alopecia will be excluded.
* Other scalp disease that may impact AA assessment (eg, scalp psoriasis, dermatitis, etc.).
* Active systemic diseases that may cause hair loss (eg, lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc).

Where it's running

• California Dermatology & Clinical Research Institute
  Encinitas, California, United States Recruiting
• Skin Research of South Florida
  Miami, Florida, United States Recruiting
• Dawes Fretzin Clinical Research Group, LLC
  Indianapolis, Indiana, United States Recruiting
• Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
  Boston, Massachusetts, United States Recruiting
• Revival Research Institute, LLC
  Troy, Michigan, United States Recruiting
• Clinical and Translational Research Center (CTRC)
  Chapel Hill, North Carolina, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing two doses of ritlecitinib for treating alopecia areata in people aged 12 and older

  This study is testing two different doses of a new oral medication called ritlecitinib to see if it can help people aged 12 and older with significant hair loss from alopecia areata.

  Recruiting at 41 sites Phase 3 Pfizer · Birmingham, Alabama and 147 other locations · NCT06873945

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata

  This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07803874

• VC005 tablets in teens with severe alopecia areata

  This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.

  Recruiting Phase 1 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07762443

• VC005 tablets in severe alopecia areata

  This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.

  Recruiting Phase 2 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07749716

• Alopecia Areata: looking at ferroptosis markers in blood

  This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Cerrahpasa Mahallesi · NCT07733063

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.